Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer drug discovery: the wisdom of imprecision

Drug discovery is either an exact business that is based on detailed knowledge of target structure or it is a fishing expedition that uncovers new drugs through screening of random compounds for their biological effect on target function. Isolation of a new p53 activator with anticancer properties strengthens the reputation of this second approach (pages 1321–1328).

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Disrupting p53–HDM-2 interaction by small molecules: two targeting approaches.


  1. Issaeva, N. et al. Nat. Med. 10, 1321–1328 (2004).

    CAS  Article  Google Scholar 

  2. Fischer, P.M. & Lane, D.P. Trends Pharmacol. Sci. 25 343–346 (2004).

    CAS  Article  Google Scholar 

  3. Vassilev, L.T. et al. Science 303, 844–848 (2004).

    CAS  Article  Google Scholar 

  4. Bykov, V.J. et al. Nat. Med. 8, 282–288 (2002).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gudkov, A. Cancer drug discovery: the wisdom of imprecision. Nat Med 10, 1298–1299 (2004).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing